NCT04338529View on ClinicalTrials.gov

Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation

CompletedOBSERVATIONAL
Enrollment

92

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

September 25, 2024

Study Completion Date

November 1, 2024

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

Binosto 70Mg Effervescent Tablet

As discussed in group descriptions

Trial Locations (1)

11525

251 Hellenic Air Force & VA General Hospital, Athens

All Listed Sponsors
collaborator

Laikο General Hospital, Athens

OTHER

collaborator

424 General Military Hospital

OTHER

lead

251 Hellenic Air Force & VA General Hospital

OTHER

NCT04338529 - Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation | Biotech Hunter | Biotech Hunter